AlphAIAlphAI — Financial news for AI agents
247wallst.comOCT 92 min read

TRex Bio raises $116.7 million in IPO priced at $14 a share

TRex Bio Inc. raised $116.7 million in its IPO, priced at $14 per share. J.P. Morgan and Evercore led the offering, indicating institutional confidence. The company focuses on immunology, an area of sustained investor interest. All shares were pre-allocated to institutional buyers, with the first public trading opportunity upcoming.

Original reporting
247wallst.com
Published Oct 9, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TRex Bio raises $116.7 million in IPO priced at $14 a share — source image
Source · 247wallst.com
Decision brief

The 30-second read

High
01

Why it matters

The IPO provides immediate trading opportunity and sets a valuation benchmark for similar immunology biotech firms.

02

Market read

First‑day trading of TRex Bio offers a fresh entry point for investors interested in immunology biotech, with potential spillover to peer stocks.

03

What to watch

Potential dilution from future financing rounds and regulatory hurdles.

Relevance 8/10Novelty 9/10Timing: pre-market today

Background

TRex Bio priced its IPO at $14 per share, raising $116.7 million, with J.P. Morgan and Evercore as joint book‑running managers.

Market effects

Sector

Adds new supply to the immunology biotech sector, may boost peer valuations.

Regional

US biotech IPO market sees fresh capital inflow.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

The IPO price may be overvalued given early-stage pipeline risk.

Key entities

  • company
    TRex Bio, Inc.

    Immunology biotech company launching its IPO.

  • financial_institution
    J.P. Morgan

    Joint book‑running manager for the IPO.

  • financial_institution
    Evercore

    Joint book‑running manager for the IPO.

Read at source← All news

StoryTRex Bio completes $116.7 million IPO at $14 per share

Also covered by

1 outlet

Related articles

NOV 4
$TREXHigh

Trex earnings beat by $0.07, revenue topped estimates

Trex (TREX) reported Q3 EPS of $0.55, beating estimates by $0.07, with revenue at $360M, exceeding expectations of $314.85M. The company guided Q4 2026 revenue to $175M-$185M, above consensus of $167.90M, and FY 2026 revenue to $1.29B-$1.31B, above consensus of $1.24B. The stock is up 1.69% in 3 months and 54.18% in 12 months.

investing.com1 min
NOV 4
$TREXHighAI 8/10

Trex (NYSE:TREX) reports upbeat Q3 2026, stock soars

Trex (TREX) reported Q3 2026 revenue of $359.5M, beating estimates by 14.3% and growing 26% YoY. Adjusted EPS was $0.55, a 15.4% beat. Q4 revenue guidance is $180M, above consensus. Full-year EBITDA guidance is $357.5M, also above estimates. Operating and free cash flow margins declined YoY.

finance.yahoo.com2 min
NOV 4
$TREXMed

Trex: Q3 Earnings Snapshot

Trex Co. (TREX) reported Q3 profit of $52.5M, or 52 cents per share, beating analyst estimates of 49 cents. Revenue was $359.5M, exceeding forecasts of $315.8M. The company expects full-year revenue between $1.3B and $1.31B.

finance.yahoo.com1 min